These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32386980)

  • 1. Design, synthesis and biological evaluation of N-hydroxy-aminobenzyloxyarylamide analogues as novel selective κ opioid receptor antagonists.
    He G; Song Q; Wang J; Xu A; Peng K; Zhu Q; Xu Y
    Bioorg Med Chem Lett; 2020 Jul; 30(13):127236. PubMed ID: 32386980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of aminobenzyloxyarylamide derivatives as selective κ opioid receptor antagonists.
    Wang J; Song Q; Xu A; Bao Y; Xu Y; Zhu Q
    Eur J Med Chem; 2017 Apr; 130():15-25. PubMed ID: 28237793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.
    Jackson KJ; Jackson A; Carroll FI; Damaj MI
    Neuropharmacology; 2015 Oct; 97():270-4. PubMed ID: 26044637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human.
    Rorick-Kehn LM; Witcher JW; Lowe SL; Gonzales CR; Weller MA; Bell RL; Hart JC; Need AB; McKinzie JH; Statnick MA; Suico JG; McKinzie DL; Tauscher-Wisniewski S; Mitch CH; Stoltz RR; Wong CJ
    Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25637376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
    J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Improved Antagonist Radiotracer for the κ-Opioid Receptor: Synthesis and Characterization of (11)C-LY2459989.
    Zheng MQ; Kim SJ; Holden D; Lin SF; Need A; Rash K; Barth V; Mitch C; Navarro A; Kapinos M; Maloney K; Ropchan J; Carson RE; Huang Y
    J Nucl Med; 2014 Jul; 55(7):1185-91. PubMed ID: 24854795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: Design, synthesis, pharmacology and molecular modeling studies.
    Schmitt S; Colloc'h N; Perrio C
    Eur J Med Chem; 2015 Jan; 90():742-50. PubMed ID: 25513968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology.
    Margolis EB; Wallace TL; Van Orden LJ; Martin WJ
    PLoS One; 2020; 15(12):e0232864. PubMed ID: 33373369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors.
    Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A
    Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.
    Yuan Y; Zaidi SA; Elbegdorj O; Aschenbach LC; Li G; Stevens DL; Scoggins KL; Dewey WL; Selley DE; Zhang Y
    J Med Chem; 2013 Nov; 56(22):9156-69. PubMed ID: 24144240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.
    Mitch CH; Quimby SJ; Diaz N; Pedregal C; de la Torre MG; Jimenez A; Shi Q; Canada EJ; Kahl SD; Statnick MA; McKinzie DL; Benesh DR; Rash KS; Barth VN
    J Med Chem; 2011 Dec; 54(23):8000-12. PubMed ID: 21958337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.
    Zheng Y; Obeng S; Wang H; Stevens DL; Komla E; Selley DE; Dewey WL; Akbarali HI; Zhang Y
    ACS Chem Neurosci; 2018 Dec; 9(12):3028-3037. PubMed ID: 30001114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).
    Kormos CM; Ondachi PW; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA; Fennell TR; Snyder RW; Carroll FI
    J Med Chem; 2018 Sep; 61(17):7546-7559. PubMed ID: 30032602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.
    Zheng Z; Huang XP; Mangano TJ; Zou R; Chen X; Zaidi SA; Roth BL; Stevens RC; Katritch V
    J Med Chem; 2017 Apr; 60(7):3070-3081. PubMed ID: 28339199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Structure-Activity Relationship Comparison of Imidazodiazepines Binding at Kappa, Mu, and Delta Opioid Receptors and the GABA
    Li G; Nieman AN; Mian MY; Zahn NM; Mikulsky BN; Poe MM; Methuku KR; Liu Y; Cook JM; Stafford DC; Arnold LA
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32854311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin.
    Joshi AA; Murray TF; Aldrich JV
    J Med Chem; 2015 Nov; 58(22):8783-95. PubMed ID: 26491810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of the in vivo selectivity of a new κ-opioid receptor antagonist PET tracer 11C-LY2795050 in the rhesus monkey.
    Kim SJ; Zheng MQ; Nabulsi N; Labaree D; Ropchan J; Najafzadeh S; Carson RE; Huang Y; Morris ED
    J Nucl Med; 2013 Sep; 54(9):1668-74. PubMed ID: 23918735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).
    Ondachi PW; Kormos CM; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA; Fennell TR; Snyder RW; Carroll FI
    J Med Chem; 2018 Sep; 61(17):7525-7545. PubMed ID: 30117738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.